Kineta, Inc. was formed in December 2007 by a group of scientists who are internationally recognized for breakthrough discoveries on the human immune system and the body's reaction to the hepatitis C virus. Through Kineta, their third company, the team is developing new innovative therapies that tap into naturally present innate and adaptive immune functions for the treatment of infectious and autoimmune diseases. Kineta has an aggressive strategy to move novel early stage products into the clinical pipeline. We believe our novel approach to science and business will yield new classes of drugs for diseases that afflict millions of people around the world and also align with growing pharmaceutical markets.